Arlington, MA, United States of America

Suresh K Tipparaju

This inventor holds 9 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignees: Akagera Medicines, Inc., Celator Pharmaceuticals, Inc., Merrimack Pharmaceuticals, Inc.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Suresh K Tipparaju. Retrieved from https://idiyas.com/inventor/suresh-k-tipparaju

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

% Patents Active = 77.8

 

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2020-2026

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Inventive Journey of Suresh K Tipparaju

Introduction: Suresh K Tipparaju is a prolific inventor based in Arlington, MA, known for his innovative contributions in various fields.

Latest Patents: Suresh K Tipparaju holds several patents in the areas of technology, healthcare, and consumer products, showcasing his diverse range of interests and expertise.

Career Highlights: With a background in engineering and a passion for problem-solving, Suresh K Tipparaju has had a successful career marked by groundbreaking inventions that have made a significant impact in their respective industries.

Collaborations: Throughout his career, Suresh K Tipparaju has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Suresh K Tipparaju's dedication to innovation and his relentless pursuit of new ideas continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…